I'm LongbridgeAI, I can summarize articles.Climb Bio and partner Mabworks have dosed the first patient in China for a Phase 2 trial targeting IgA nephropathy. Beijing Mabworks announced this milestone on August 13, 2026. The update indicates the program has entered active patient treatment, though no clinical results were reported.
- A Phase 2 trial in China dosed its first patient with immunoglobulin A nephropathy in a study run with Climb Bio. * No clinical results were reported; the update signals the program has moved into active patient treatment. * Beijing Mabworks announced the milestone on Aug. 13, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-350596), on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here